BioTime Licenses Weill Cornell-Developed Vascular Cells Technology; Anti-Cancer Tumor Potential

BioTime, Inc. announced today it has entered into an exclusive agreement with Cornell University for the worldwide development and commercialization of technology developed at Weill Cornell Medical College for the differentiation of human embryonic stem cells into vascular endothelial cells. Potential uses of this technology may include a new modality for targeting cancer tumors.

Vascular endothelial cells form the blood vessels that support the growth of cancerous tumors. The technology may be used to derive vascular endothelial cells engineered to “deliver a toxic payload to the developing blood vessels of a tumor to remove malignant tumors while not affecting nearby normal tissues.”

Click here to read the full article.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible. View all posts by lymphomaprogram